文献速递肾癌与肾肿瘤

伴有静脉瘤栓的肾细胞癌的减瘤性肾切除术

Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus.
PubMed 文献 · J Urol · 2017-03-06

该多中心回顾性研究纳入2000至2014年5家机构427例伴静脉瘤栓的转移性肾细胞癌患者,评估术前变量及风险分层系统对减瘤性肾切除术后总生存的预测价值。膈上下腔静脉瘤栓患者中位总生存9.2个月,短于仅肾静脉瘤栓者的21.7个月(p=0.0165)。独立预测因素包括乳酸脱氢酶高于正常上限、全身症状、膈上下腔静脉瘤栓及肉瘤样特征。

要点

  • 膈上下腔静脉瘤栓患者中位总生存9.2个月,短于仅肾静脉瘤栓者的21.7个月(p=0.0165)。
  • 乳酸脱氢酶高于正常上限、全身症状、膈上瘤栓及肉瘤样特征为总生存独立预测因素。
  • 预期总生存差的患者应考虑参加术前全身治疗临床试验。

核心结论

  • 伴瘤栓的转移性肾细胞癌患者减瘤性肾切除术后总生存差与膈上 下腔静脉瘤栓、不良风险组、全身症状或肉瘤样去分化相关。
  • 预期总生存差的患者应考虑参加术前全身治疗临床试验。

研究设计与样本

  • 多中心回顾性研究,纳入2000至2014年5家机构427例伴静脉瘤栓的转移性肾细胞癌患者。
  • 评估术前变量及转移性肾细胞癌风险模型与总生存的关联,采用多变量分析确定独立关联。

主要发现

  • 膈上 下腔静脉瘤栓患者中位总生存9.2个月(IQR 4.2-30.8),仅肾静脉瘤栓患者为21.7个月(IQR 7.7-42.8),p=0.0165。
  • 122例(32%)患者在术后270天内死亡。
  • 总生存独立预测因素包括乳酸脱氢酶高于正常上限(p=0.003)、全身症状(p=0.003)、膈上 下腔静脉瘤栓(p=0.02)及肉瘤样特征(p=0.005)。

临床怎么用

  • 作者认为,预期总生存差的患者应考虑参加术前全身治疗临床试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Careful selection is critical to identify those with metastatic renal cell carcinoma who are most likely to benefit from cytoreductive nephrectomy. Surgery in patients who have metastatic renal cell carcinoma with tumor thrombus is complex and may not benefit some patients with poor overall survival. We evaluated whether preoperative variables or risk stratification systems could predict overall survival following cytoreductive nephrectomy. MATERIALS AND METHODS: Prognostic factors for overall survival after surgery were evaluated in patients who had metastatic renal cell carcinoma with venous tumor thrombus at 5 institutions from 2000 to 2014. Prognostic variables, including metastatic renal cell carcinoma risk models, were evaluated for associations with overall survival. Multivariable analysis was used to determine independent associations of preoperative variables with overall survival. RESULTS: A total of 427 patients with metastatic renal cell carcinoma were identified with tumor thrombus. Patients with inferior vena cava thrombus above the diaphragm had shorter median overall survival vs those with renal vein only thrombus (9.2 months, IQR 4.2-30.8, vs 21.7, IQR 7.7-42.8, p = 0.0165). Individual risk factors from prognostic models were evaluated among other preoperative characteristics for associations with overall survival in 122 patients (32%) who died within 270 days of surgery. Independent predictors of overall survival included lactate dehydrogenase greater than the upper limit of normal (p = 0.003), systemic symptoms (p = 0.003), inferior vena cava thrombus above the diaphragm (p = 0.02) and sarcomatoid features (p = 0.005). CONCLUSIONS: Poor overall survival following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma with tumor thrombus is associated with inferior vena cava thrombus above the diaphragm, poor risk group, systemic symptoms or sarcomatoid dedifferentiation. Patients with expected poor overall survival should be considered for preoperative systemic therapy clinical trials.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Abel EJ, Spiess PE, Margulis V, et al. Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus. J Urol. 2017. PMID: 28268170. doi:10.1016/j.juro.2017.03.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。